21st International Congress » Other

1:15pm-2:45pm

3D image as a complimentary assist in patients with Parkinson’s disease

D. Khodjieva, N. Mansurova, N. Khaydarov (Bukhara, Uzbekistan)

1:15pm-2:45pm

A combined cognitive and motor exercise program for people with Parkinson’s disease and Freezing of gait; a pilot study.

L. King, K. Smulders, M. Mancini, J. Lapidus, P. Carlson-Kuhta, B. Fling, J. Nutt, F. Horak (Portland, OR, USA)

1:15pm-2:45pm

Availability of anti-Parkinsonian drugs in Thailand

K. Sakdisornchai, R. Bhidayasiri, O. Jitkritsadakul, p. panyakaew, J. Sringean (Bangkok, Thailand)

1:15pm-2:45pm

Baseline predictors for clinical progression after 48 month follow-up in early Parkinson’s disease from the DeNoPa cohort

B. Mollenhauer, J. Zimmermann, F. Sixel-Döring, N. Focke, T. Wicke, J. Ebentheuer, M. Schaumburg, E. Lang, C. Trenkwalder (Kassel, Germany)

1:15pm-2:45pm

Characterization of Pisa syndrome in Parkinson’s disease.

T. Clark, J. Nutt, F. Horak, M. Mancini, M. Jurado, T. Hullar (Portland, OR, USA)

1:15pm-2:45pm

Characterizing task-based acoustic variations of vowels in Parkinson’s disease: Preliminary data

C. Kuo (Harrisonburg, VA, USA)

1:15pm-2:45pm

Cinnamomum verum on Learning and Memory in Wistar Albino Rats

N. AHMED, D. AGRAWAL, A. CHUGHTAI (ALIGARH, India)

1:15pm-2:45pm

Clinical and electrophysiological features of seven patients with moving toes syndrome: Is it a type of spinal segmental myoclonus?

G. Kiziltan, H. Kurucu, C. Yalcinkaya, A. Gunduz, M. E. Kiziltan (Istanbul, Turkey)

1:15pm-2:45pm

Clinical Criteria for Subtyping Parkinson’s Disease: Differences in imaging and CSF biomarkers and longitudinal progression

S.-M. Fereshtehnejad, Y. Zeighami, A. Dagher, R. Postuma (Montreal, QC, Canada)

1:15pm-2:45pm

CSF, plasma and saliva alpha-Synuclein in moderately advanced Parkinson’s disease cohort: the BioFIND study

R. Alcalay, A. Amara, P. Taylor, H. Andrews, J. Goldman, T. Xi, P. Tuite, C. Henchcliffe, P. Hogarth, S. Frank, M.-H. Saint Hilaire, A. Naito, M. Frasier, V. Arnedo, A. Reimer, M. Sutherland, C. Swanson-Fischer, K. Gwinn, U. Kang (NYC, NY, USA)

1:15pm-2:45pm

Death in patients with Parkinson’s disease – an observational study

R. Mappilakkandy, A. Pieris, D. Miodrag, A. Chunduri (Northampton, United Kingdom)

1:15pm-2:45pm

Developing a guide to facilitate involving people with Parkinson’s and their carers in service improvement

N. Shaw, V. Evans, J. Rideout, C. Carroll (Plymouth, United Kingdom)

1:15pm-2:45pm

Development of a Clinical Outcomes Assessment (COA) in Pantothenate-Kinase Associated Neurodegeneration (PKAN): Item Generation and Clinimetric Properties

R. Marshall, A. Collins, M. Escolar, H.A. Jinnah, T. Klopstock, M. Kruer, A. Videnovic, A. Robichaux-Viehoever, L. Swett, D. Revicki, R. Bender, W. Lenderking (Cambridge, MA, USA)

1:15pm-2:45pm

Development of utility to evaluate a symptomatic diary of motor fluctuations of Parkinson’s disease (PD) using a smartphone application.

H. Ohtsubo, H. Iwaki, H. Yabe, M. Nagai, M. Nomoto (Matsuyama Ehime, Japan)

1:15pm-2:45pm

Differences between Hemifacial spasm with or without neurovascular conflict. Therapeutic implications with botulinum toxin type A.

J.S. Bestoso, L. Ciancaglini, C. Stefani, C. Azcona, M.L. Contartese, A. Pappolla, J.I. Rojas, D. Bauso (Buenos Aires, Argentina)

1:15pm-2:45pm

Disease modeling for Perry syndrome using patient induced pluripotent stem cells

T. Mishima, T. Ishikawa, K. Imamura, T. Kondo, Y. Koshiba, R. Takahashi, J. Takahashi, A. Watanabe, N. Fujii, Y. Tsuboi, H. Inoue (Fukuoka, Japan)

1:15pm-2:45pm

Effect of object size and obstacle avoidance on of Reach-to-Grasp Actions in Individuals with Parkinson’s disease

S. Khacharoen, J. Tretriluxana, P. Srivanitchapoom, A. Pisarnpong, T. Chandharohit (Nakhon Pathom, Thailand)

1:15pm-2:45pm

Elevated GM3 Plasma Concentration in Idiopathic Parkinson’s Disease: a Lipidomics Analysis

R. Alcalay, R. Chan, C. Liong, A. Perotte, B. Zhou, E. Shorr, K. Marder, U. Kang, C. Waters, O. Levy, Y. Xu, H. Shim, I. Pe'er, G. Di Paolo (New York, NY, USA)

1:15pm-2:45pm

End of Life Care in Parkinson’s Disease

S. Mole, S. Jackson (Exeter, United Kingdom)

1:15pm-2:45pm

Epidemiological profile and challenges of a reference public center for the treatment of neurological conditions using botulinum toxin type A: experience of a North-eastern center in Brazil.

R. Prado, W. Cunha, P. Macêdo, A. Santiago, R. Sá, J. Santos, M. Machado (Aracaju, Brazil)

1:15pm-2:45pm

Epilepsy and Cranial nerve affection in a Patient with Wilson’s disease and Intracranial developmental venous anomaly; A Case Report

W. Ezzat, A. Mohamed (cairo, Egypt)

1:15pm-2:45pm

Evaluating the Experience of Diagnosis in Parkinson’s Disease

A. Robinson, E. Pearson, F. Murphy, J. Davis, C. Carroll (Plymouth, United Kingdom)

1:15pm-2:45pm

Extrapyramidal signs in neurosarcoidosis versus multiple sclerosis: is TNF alpha the link?

T. Drori, J. Chapman, M. Lidar, P. Langevitz, Y. Shoenfeld, O. Cohen (Ramat-Gan, Israel)

1:15pm-2:45pm

Falls characteristics of male and female patients with Parkinson’s disease (PD)

G. Alg, A. Chatterjee, F. Zahir (Reading, United Kingdom)

1:15pm-2:45pm

Falls in Parkinson’s disease are related to delayed recovery time after unexpected external perturbations

V. Beretta, F. Barbieri, D. Orcioli-Silva, P. Santos, M. Pereira, R. Vitório, L. Gobbi (Rio Claro, Brazil)

1:15pm-2:45pm

Gait and Balance Impairment After Methanol Intoxication

K. Peterová, H. Brožová, J. Klempíř, I. Lišková, S. Zakharov, O. Bezdíček, M. Vaněčková, Z. Seidl, E. Růžička (Prague, Czech Republic)

1:15pm-2:45pm

Gait asymmetry and asymmetry index in a sample of patients with PD and control group in Cali – Colombia.

B. Munoz, A. Enriquez-Marulanda, J. Orozco (Cali, Colombia)

1:15pm-2:45pm

High intensity interval training improves psychomotor function in individuals with Parkinson’s disease

J. Marusiak, B. Fisher, A. Jaskólska, K. Słotwinski, S. Budrewicz, M. Koszewicz, K. Kisiel-Sajewicz, A. Jaskólski (Wroclaw, Poland)

1:15pm-2:45pm

Immunomodulatory therapy in stiff-person syndrome (SPS): a controlled Rituximab-randomised study

M. Amarandei (Bucharest, Romania)

1:15pm-2:45pm

In-patient Parkinson courses and caregiver burden

K. Martikainen, S. Kinos, R. Marttila (Turku, Finland)

1:15pm-2:45pm

Incorporating Specialist Independent Prescribing Pharmacist (SIPP) sessions into the Movement Disorder Service

D. Fletcher, E. Thomas, B. Mohamed (Cardiff, United Kingdom)

1:15pm-2:45pm

Inpatient care for stiff person syndrome in the United States: A nationwide readmission study

J. Crispo, D. Thibault, Y. Fortin, A. Willis (Sudbury, ON, Canada)

1:15pm-2:45pm

Management of fragility fractures in Parkinson’s Disease (PD)

G. Alg, A. Chatterjee (Reading, United Kingdom)

1:15pm-2:45pm

Motor Heterogeneity in Parkinson’s Disease: A Bayesian Perspective

A. Johnson, A. Loftus, N. Gasson, B. Lawrence, M. Thomas, R. Bucks (Perth, Australia)

1:15pm-2:45pm

Movement Disorders in Demyelinating Diseases: a retrospective review from a tertiary academic center.

G. Suarez-Cedeno, M. Raja (Houston, TX, USA)

1:15pm-2:45pm

Multidisciplinary intensive outpatient rehabilitation program for patients with advanced Parkinson’s disease: feasibility and primary proof of concept

T. Gurevich, T. GAIL, n. choen, o. KADURRI, L. SHTRAIFLER, I. BADICHI, N. RIPS CASSERI (tel aviv, Israel)

1:15pm-2:45pm

Neural correlates of movement sequence kinematics in substantia nigra dopaminergic cells

M. Mendonça, J. Alves Silva, L. Hernandez, J. Obeso, R. Costa (Lisboa, Portugal)

1:15pm-2:45pm

Neuroprotective propensity of PTUPB, a dual inhibitor of sEH and COX-2 against rotenone induced neurotoxicity in cell line and Drosophila model of Parkinson disease

N. Lakkappa, P. Thaggikuppe Krishnamurthy, P.D. Mirazkar, N. Lakkappa, P. Krishnamurthy, P.M.D., M.M. Srinivas Bharath, B. Hammock, S.H. Hwang (Udhagamandalam, India)

1:15pm-2:45pm

New method to evaluate new motor skill learning

A.P. Quixadá, V. Sotero, J.-F. Daneault, G. Diaz, Â. Torres, J.P. Vieira, M. Fonseca, P. Bonato, N. Peña, J.G. Miranda (Salvador, Brazil)

1:15pm-2:45pm

NS-PARK/FCRIN network, the French Clinical Research Network for Parkinson’s disease and Movement Disorders

E. Dellapina, V. Chaigneau, F. Durif, J.-C. Corvol, O. Rascol, F. NS-PARK/FCRIN network (Toulouse, France)

1:15pm-2:45pm

Ocular Motor Disorders Among Filipino “LUBAG” or X-Linked Dystonia Parkinsonism (XDP) Patients

M. Macas, E.C. Rossi, S. Abantas-Diamla, A. Punzalan-Sotelo, E. Palisoc, C. Go (Manila, Philippines)

1:15pm-2:45pm

Optimization and evaluation of whole body MRI sequences for patients with deep brain stimulators

C. Drews, S. Wolff, L. Lunden, O. Jansen (Kiel, Germany)

1:15pm-2:45pm

Oscillatory Activity in the Nucleus Basalis of Meynert

M. Nazmuddin, D. Oterdoom, J. van Zijl, A. Kampman, J. van Dijk, G. Drost, T. van Laar, M. Beudel (Groningen, Netherlands)

1:15pm-2:45pm

Patients affected by functional motor symptoms are not liars: an experimental deception study with the Guilty Knowledge Task

B. Demartini, R. Ferrucci, D. Goeta, F. Ruggiero, A. Priori, O. Gambini (Milano, Italy)

1:15pm-2:45pm

Physical Activity in Early Parkinson Disease

S. Mantri, M. Fullard, J. Duda, J. Morley (Philadelphia, PA, USA)

1:15pm-2:45pm

Polyneuropathy in patients with Parkinson’s disease from southern Spain treatment with levodopa/carbidopa intestinal gel infusión

F. Carrillo, S. Jesus, L. Vargas, M. Bernal, M.T. Caceres, A.D. Adarmes, M. Carballo, P. Mir (Seville, Spain)

1:15pm-2:45pm

Pregnancy and Parkinson’s disease: A review and update

M. Seier, A. Hiller (Portland, OR, USA)

1:15pm-2:45pm

Prevalence of Babinski-2 sign in Hemifacial Spasm Patients

O. Dogu, H. Kalegasi (Mersin, Turkey)

1:15pm-2:45pm

Self Perception of Dysphagia in Parkinson Disease

A. Silbergleit, C. Sidiropoulos, R. Konnai, L. Schultz, A. Kitowski, P. LeWitt (West Bloomfield, MI, USA)

1:15pm-2:45pm

Some clincal features of movement disorders after cerebral anoxia.

B. Tserensodnom (Ulaanbaatar, Mongolia)

1:15pm-2:45pm

Stiff-limb syndrome with cerebellar features and atypical EMG findings responds to IVIG

S. Rametta, G. Robinson, N. Hellmers, N. Jacoby, H. Sarva (Brooklyn, NY, USA)

1:15pm-2:45pm

The combination of clinical scales and walking measures to predict falls in Parkinson’s disease: Does the length of the prospective follow-up period matter?

R. Vitório, R. Moraes, A. Baptista, E. Lirani-Silva, L. Simieli, D. Orcioli-Silva, F. Barbieri, L. Gobbi (Rio Claro, Brazil)

1:15pm-2:45pm

The effects of wearing usual indoor and outdoor footwear on balance and gait performance in people with Parkinson’s disease using clinical tests and instrumented movement analysis.

D. Kunkel, M. Burnett, L. Mamode, R. Pickering, C. Bowen, D. Bader, J. Robison, M. Donovan-Hall, M. Cole, A. Ashburn (Southampton, United Kingdom)

1:15pm-2:45pm

The management of Parkinson’s disease in the Middle East countries: the MDS-middle east task force survey

H. Khalil, Z. Aldaajani, S. Baudry, M. Abualmelh, T. Mohammad, M. Salari, M. Bhatt, S. Tabbal, N.A. Syed, B. Jeon, C. Goetz, J.A. Bajwa (Irbid, Jordan)

1:15pm-2:45pm

The Pull Test in healthy subjects and Parkinson´s disease: quantitative pull-force measure, postugraphic and electromyographic analysis

J.R. Perez-Sanchez, B. DeLaCasa-Fages, A. Contreras, J.M. Velázquez, A. Muñoz-González, F. Grandas (Madrid, Spain)

1:15pm-2:45pm

The Use of Atypical Antipsychotics in Depression and Anxiety may Unmask Parkinson’s Disease: A Retrospective Chart Review

K. Amodeo, R. Schneider, I. Richard (Rochester, NY, USA)

1:15pm-2:45pm

Treatment of Functional Neurological Disorders: Towards Expert Consensus Led Guidelines for the American Neuropsychiatric Association Committee for Research

O. Ghaffar, M. Modirrousta, C. LaFrance, N. Williams, R. Shura, S. Ducharme, V. Voon (Whitby, ON, Canada)

1:15pm-2:45pm

Validation of the MDS Research Criteria for Prodromal Parkinson’s Disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort

S.-M. Fereshtehnejad, J. Montplaisir, A. Pelletier, J.-F. Gagnon, D. Berg, R. Postuma (Montreal, QC, Canada)

1:15pm-2:45pm

Vascular hemiballismus due to a lentiform nucleus infarct

D. Gams Massi, J. Nyassinde, K. Toure, N.S. Diagne, M. Ndiaye, A.G. Diop, M.M. Ndiaye (Dakar, Senegal)